Latest From ContraFect Corp.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Appointments: Gilead, Shield Therapeutics, Gelesis, TG Therapeutics, Aziyo Biologics, Allogene Therapeutics, Mesoblast and CGT Catapult Make New Hires
Latest appointments announced by pharma and biotech firms.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- ContraFect Corp.
- Senior Management
Roger J Pomerantz, MD, Chmn. & CEO
Michael Messinger, SVP, Fin.
Cara Cassino, MD, CMO & EVP, R&D
- Contact Info
Phone: (914) 207-2300
28 Wells Ave., 3rd Fl.
Yonkers, NY 10701
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.